Stockscreener 앱 받기
1.02
0.97%
-0.01
시간 외 거래:
1.01
-0.01
-0.98%
전일 마감가:
$1.03
열려 있는:
$0.9807
하루 거래량:
221.43K
Relative Volume:
0.69
시가총액:
$45.95M
수익:
$1.12M
순이익/손실:
$-11.17M
주가수익비율:
-3.2268
EPS:
-0.3161
순현금흐름:
$-10.98M
1주 성능:
+8.63%
1개월 성능:
+22.14%
6개월 성능:
-20.93%
1년 성능:
+13.33%
1일 변동 폭
$0.9806
$1.0299
1주일 범위
$0.92
$1.0799
52주 변동 폭
$0.7006
$1.45
Renovorx Inc Stock (RNXT) Company Profile
명칭
Renovorx Inc
전화
408-800-2649
주소
2570 W. EL CAMINO REAL, STE. 320,, MOUNTAIN VIEW
Compare RNXT vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RNXT
Renovorx Inc
|
1.02 | 46.40M | 1.12M | -11.17M | -10.98M | -0.3161 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Renovorx Inc 주식(RNXT)의 최신 뉴스
Clinical Data Supporting Targeted Chemotherapeutic Delivery via RenovoRx's TAMP Therapy Platform Presented at 2026 SIR Annual Scientific Meeting - marketscreener.com
RenovoRx Inc Presents Clinical Data Supporting Targeted Chemotherapeutic Delivery Via Tamp Therapy Platform - marketscreener.com
Clinical Data Supporting Targeted Chemotherapeutic Delivery via RenovoRx’s TAMP™ Therapy Platform Presented at 2026 SIR Annual Scientific Meeting - The Manila Times
Pancreatic cancer scans show early response after artery-delivered chemo - Stock Titan
Fund Flows: Is RenovoRx Inc exposed to political risk2026 Trading Volume Trends & Real-Time Sentiment Analysis - baoquankhu1.vn
Meme Stocks: Is RenovoRx Inc a defensive stockWeekly Trade Review & Fast Exit and Entry Strategy Plans - baoquankhu1.vn
RenovoRx Announces Closing of Oversubscribed $10 Million at Market Private Placement - ADVFN
Signal Recap: Whats the outlook for RenovoRx Incs sector2026 Sector Moves & Free Fast Gain Swing Trade Alerts - baoquankhu1.vn
RenovoRx (RNXT) price target increased by 18.52% to 8.16 - MSN
RenovoRx receives Japanese patent for RenovoCath device By Investing.com - Investing.com Australia
RNXT: HC Wainwright Reiterates Buy Rating and $3.00 Price Target - GuruFocus
RenovoRx Secures First Notice of Allowance for Japanese Patent Covering its RenovoCath Device for Targeted, Local Drug-Delivery via the Vasa Vasorum - Bitget
RenovoRx receives Japanese patent for RenovoCath device - Investing.com
RenovoRx Secures First Notice of Allowance for Japanese Patent Covering its RenovoCath® Device for Targeted, Local Drug-Delivery via the Vasa Vasorum - Investing News Network
Cancer drug-delivery device wins Japan patent allowance as RenovoRx expands - Stock Titan
RenovoRx (NASDAQ: RNXT) CEO receives 946,107 stock options grant - Stock Titan
RenovoRx (RNXT) CMO granted 621,727 options vesting through 2030 - Stock Titan
Stock Recap: How does RenovoRx Inc perform in inflationary periods2026 Historical Comparison & Risk Managed Investment Entry Signals - baoquankhu1.vn
RenovoRx, Inc. Appoints Ramtin Agah, M.D. As Executive Chairman , Effective February 27, 2026 - marketscreener.com
RNXT Technical Analysis & Stock Price Forecast - Intellectia AI
Analysts Offer Insights on Healthcare Companies: AbSci (ABSI) and RenovoRx (RNXT) - The Globe and Mail
RenovoRx Named to Fast Company’s Annual List of the World’s Most Innovative Companies of 2026 - Taiwan News
Street Watch: How does RenovoRx Inc perform in inflationary periods2026 Price Action Summary & Reliable Price Breakout Signals - baoquankhu1.vn
RenovoRx Named to Fast Company's Annual List of the World's Most Innovative Companies of 2026 - 富途牛牛
RenovoRx Reports 2025 Results and Advances TIGeR-PaC Trial - The Globe and Mail
RNXT SEC FilingsRenovorx Inc 10-K, 10-Q, 8-K Forms - Stock Titan
RenovoRx Reports Solid First Full Year of RenovoCath Commercialization - National Today
RenovoRx earnings beat, revenue fell short of estimates By Investing.com - Investing.com Canada
RenovoRx Inc (RNXT) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... By GuruFocus - Investing.com Canada
Trade Recap: What chart patterns are forming on RenovoRx IncMarket Performance Summary & Daily Oversold Stock Bounce Ideas - baoquankhu1.vn
RenovoRx Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Published on: 2026-03-31 14:32:17 - baoquankhu1.vn
RNXT: 2026 revenue is projected to triple as commercial site expansion accelerates and funding strengthens - TradingView
Earnings call transcript: RenovoRx Q4 2025 results show revenue growth By Investing.com - Investing.com South Africa
RNXT: 2025 revenue reached $1.1M, with 2026 guidance of $3–$4M and rapid commercial site expansion - TradingView
Earnings call transcript: RenovoRx Q4 2025 results show revenue growth - Investing.com
RenovoRx Reports Full Year 2025 Financial Results and Provides Business Update - Investing News Network
RNXT: 2025 revenue rose to $1.1M, but net loss increased as commercialization and R&D spending grew - TradingView — Track All Markets
RenovoRx (NASDAQ: RNXT) surges 2025 revenue and advances Phase III TIGeR-PaC - Stock Titan
RenovoRx (NASDAQ: RNXT) grows RenovoCath use and advances Phase III TIGeR-PaC - Stock Titan
RenovoRx, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
RNXT: 2025 revenue reached $1.1M as RenovoCath adoption expanded; TIGER-PAC trial nears completion - TradingView — Track All Markets
RenovoRx, Inc. (RNXT) Q4 FY2025 earnings call transcript - Yahoo Finance
RenovoRx 2025 net loss widens on higher operating expenses - TradingView — Track All Markets
BRIEF-RenovoRx FY Net Income USD -11.168 Million - TradingView
Earnings To Watch: RenovoRx Inc (RNXT) Reports Q1 2026 Result - gurufocus.com
RenovoRx Inc expected to post a loss of 8 cents a shareEarnings Preview - TradingView
RenovoRx (RNXT) CFO granted 12,380 RSUs, now reports 134,580 shares - Stock Titan
RenovoRx (RNXT) CFO discloses 25,000 shares bought pre-role - Stock Titan
RenovoRx appoints Dr. Ramtin Agah as executive chairman and updates compensation - Investing.com
[8-K] RenovoRx, Inc. Reports Material Event - stocktitan.net
Renovorx Inc (RNXT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.69%
0.25%
자본화:
|
볼륨(24시간):